

Scandinavian Real Heart AB Announces Outcome of the Exercise of Series TO 2 Warrants

NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Scandinavian Real Heart AB (publ) ("Realheart" or the "Company") today announces the outcome of the subscription period for the series TO 2 warrants ("Warrants"), which were issued in connection with the rights issue of units carried out by the Company between June 20, 2023, and July 7, 2023. A total of 17,035,600 Warrants were exercised for the subscription of 85,178 shares, corresponding to a subscription rate of approximately 51 percent of the total 33,495,885 issued Warrants. Through this exercise, Realheart will receive approximately SEK 721,000 before issuance costs.

Overview of Final Outcome

The exercise period for the Warrants ran from January 2, 2025, to January 31, 2025. The final outcome shows that 85,178 shares were subscribed through the exercise of Warrants, corresponding to an exercise rate of approximately 51 percent. The subscription price per share subscribed via the exercise of Warrants was SEK 8.47, which, in accordance with the terms of the Warrants, corresponds to 70 percent of the volume-weighted average price (VWAP) of the Company's shares on Nasdaq First North Growth Market during the measurement period. Through this exercise, Realheart will receive approximately SEK 721,000 before issuance costs.

Shares and Share Capital

As a result of the exercise of Warrants, the total number of shares in Realheart increases by 85,178, bringing the total number of outstanding shares in the Company from 2,068,152 to 2,153,330. The number of votes increases accordingly. The share capital of the Company increases by SEK 426,741.78 from SEK 10,361,441.52 to SEK 10,788,183.30, in accordance with the terms of the issuance. For existing shareholders who did not exercise any Warrants, the dilution amounts to approximately 4 percent of the total number of shares and votes in the Company after the exercise of Warrants.

Exercised Warrants will be replaced with interim shares until registration with the Swedish Companies Registration Office is completed, after which the interim shares will automatically be converted into ordinary shares. The interim shares are expected to be converted into ordinary shares approximately two banking days after registration with the Swedish Companies Registration Office.

IMPORTANT INFORMATION

The information in this press release may not be disclosed, published, or distributed, directly or indirectly, within or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or require actions beyond those required under Swedish law. Any actions in violation of this directive may constitute a breach of applicable securities laws. This press release does not constitute an offer to acquire or subscribe for securities in Realheart in any jurisdiction, either from Realheart or from any other party.

This press release is not a prospectus under the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.

This press release does not identify or purport to identify risks (direct or indirect) associated with an investment in the Company. The information in this press release is solely intended to describe the background to the exercise of the Warrants and does not claim to be comprehensive or exhaustive. No representations are made regarding the accuracy or completeness of the information in this press release.

This press release does not constitute an offer to sell or an invitation to purchase securities in the United States. The securities mentioned herein may not be sold in the United States without registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States without registration, an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to conduct a public offering of such securities in the United States.

In the United Kingdom, this document and other materials relating to the securities referred to herein are being distributed only to, and are directed only at, "qualified investors" who are (i) persons with professional experience in investment-related matters falling within the definition of "investment professionals" in Article 19(5) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities as referred to in Article 49(2)(a)-(d) of the Order (all such persons collectively referred to as "relevant persons"). Any investment or investment activity to which this announcement relates is available only to, and will only be engaged in with, relevant persons in the United Kingdom. Persons who are not relevant persons should not take any action based on this press release and should not rely on it.

For more information, please contact:

Ina Laura Perkins, CEO

Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se



PRESS RELEASE

04 February 2025 08:30:00 CET

About Us

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se